Cargando…

Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy

Immune checkpoint inhibitor (ICI) responses vary, and biomarkers for predicting responders are urgently needed. Growing evidence points to the association between programmed cell death protein ligand 2 (PDL2) and ICI benefits, while clinical evidences were lacking. Thus, we consolidated five public...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Aoyun, Chu, Han, Jin, Zheng, Jia, Qingzhu, Zhu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572643/ https://www.ncbi.nlm.nih.gov/pubmed/34754345 http://dx.doi.org/10.1155/2021/9453692

Ejemplares similares

Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment
por: Wang, Aoyun, et al.
Publicado: (2022)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy
por: Chu, Han, et al.
Publicado: (2023)

Heterogeneity of the tumor immune microenvironment and its clinical relevance
por: Jia, Qingzhu, et al.
Publicado: (2022)

Soluble Programmed Cell Death Protein 1 and Its Ligand: Potential Biomarkers to Predict Acute Kidney Injury After Surgery in Critically Ill Patients
por: Wang, Jingyi, et al.
Publicado: (2022)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy
por: Gutic, Bojana, et al.
Publicado: (2023)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer
por: Wei, Xiao-Li, et al.
Publicado: (2021)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
por: Yu, Hung-Yuan, et al.
Publicado: (2022)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Publicado: (2021)

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
por: Kareff, Samuel A., et al.
Publicado: (2021)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

GLTP Is a Potential Prognostic Biomarker and Correlates with Immunotherapy Efficacy in Cervical Cancer
por: Shi, Yan-long, et al.
Publicado: (2022)

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression
por: Zhu, Xiaodan, et al.
Publicado: (2023)

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
por: Park, Dong-Jun, et al.
Publicado: (2021)

Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy
por: Kumar, Geethu S, et al.
Publicado: (2022)

Identification of key genes of anti-programmed death ligand 1 for meningioma immunotherapy by bioinformatic analysis
por: Zhang, Lijian, et al.
Publicado: (2022)

Neoantigens in precision cancer immunotherapy: from identification to clinical applications
por: Zhang, Qiao, et al.
Publicado: (2022)

Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients
por: Yang, Haitang, et al.
Publicado: (2021)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
por: Rajakumar, Timothy, et al.
Publicado: (2022)

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy
por: Qi, Yihang, et al.
Publicado: (2021)

Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome
por: Li, Shuping, et al.
Publicado: (2022)

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
por: Fay, André P, et al.
Publicado: (2015)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

High-throughput single-сell sequencing in cancer research
por: Jia, Qingzhu, et al.
Publicado: (2022)

Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
por: Sukowati, Caecilia H C, et al.
Publicado: (2021)

Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer
por: Wang, Yuhang, et al.
Publicado: (2023)

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
por: Li, Xintong, et al.
Publicado: (2022)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy
por: Yuan, Ting, et al.
Publicado: (2023)

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer
por: Yang, Hanshen, et al.
Publicado: (2022)

The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer
por: Wei, Xiao-Li, et al.
Publicado: (2018)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Programmed death (PD)‐1/PD‐ligand 1 blockade mediates antiangiogenic effects by tumor‐derived CXCL10/11 as a potential predictive biomarker
por: Mitsuhashi, Atsushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ci5d1jvqhbgtieahnqu50n4g31